Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 1018-1021, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tertov, V. V.
Right arrow Articles by Orekhov, A. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tertov, V. V.
Right arrow Articles by Orekhov, A. N.

Clinical Chemistry, Vol 41, 1018-1021, Copyright © 1995 by American Association for Clinical Chemistry

Modified (desialylated) low-density lipoprotein measured in serum by lectin-sorbent assay

VV Tertov, IA Sobenin and AN Orekhov
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.

Modified low-density lipoprotein (LDL) with a low sialic acid content was found in the blood of patients with coronary atherosclerosis. This desialylated lipoprotein causes lipid accumulation in arterial smooth- muscle cells and stimulates cell proliferation and production of the extracellular matrix, i.e., induces all atherogenic manifestations at the cellular level. We have developed a lectin-sorbent assay for the determination of desialylated LDL in sera. The assay is based on the binding of desialylated LDL by immobilized Ricinus communis agglutinin with subsequent measurement of lipoprotein through use of anti- apolipoprotein (apo) B antibody. The assay is sensitive to desialylated apo B concentrations as low as 5 micrograms/L. The intraassay and interassay CVs were 4.8% and 11.3%, respectively. Comparison between the lectin-sorbent assay and a lectin chromatographic technique showed a good correlation. This determination of modified desialylated LDL in human serum with high accuracy and reproducibility may help establish the diagnostic value of this lipoprotein as a risk factor of atherosclerosis.


The following articles in journals at HighWire Press have cited this article:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
B. Chappey, B. Beyssen, E. Foos, F. Ledru, J. L. Guermonprez, J. C. Gaux, and I. Myara
Sialic Acid Content of LDL in Coronary Artery Disease: No Evidence of Desialylation in Subjects With Coronary Stenosis and Increased Levels in Subjects With Extensive Atherosclerosis and Acute Myocardial Infarction : Relation Between Desialylation and In Vitro Peroxidation
Arterioscler. Thromb. Vasc. Biol., June 1, 1998; 18(6): 876 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Vaysse, M. Beaugrand, and M. Pontet
Measurements of Total and Desialylated Sex Hormone-binding Globulin in Serum by ELISA
Clin. Chem., April 1, 1998; 44(4): 882 - 884.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.